Charles McDermott Email

Chairman/President/CEO . Primmune Therapeutics

Current Roles

Employees:
11
Revenue:
$852.5k
About
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.
Primmune Therapeutics Address
3210 Merryfield Row
San Diego, CA
United States
Primmune Therapeutics Email